The current uncertain landscape surrounding COVID-19 vaccines has led to major challenges for biotech companies. With reductions in funding for research and potential disruptions in the industry, experts like Cheng Li from Oppenheimer warn of long-term consequences on the development of breakthrough therapies. The shift of investments away from basic research towards more profitable areas could hinder future innovations and ultimately impact public health. Vaccine development, a critical aspect of the biotech industry, may face setbacks as a result of these changes. Stay informed on the evolving situation and its implications for the future of healthcare.
Read more about this — here
